| logout
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2022 Medicom Conference Planning
    • 2023 Medicom Conference Planning
  • Disease Areas
  • Other Medical News
  • Podcast
  • Videos
  • Education
  • About
    • Vacancies

Tag: Rituximab

Study fails to show non-inferiority of rituximab to ocrelizumab

Presented By
Dr Izanne Roos, University of Melbourne, Australia
Conference
ECTRIMS 2022

20 December, 2022 08:55

Novel first-line treatment option for mantle cell lymphoma 

Presented By
Prof. Michael Wang, Anderson Cancer Center, TX, USA
Trial
Phase 3, SHINE
Conference
ASCO 2022

5 August, 2022 14:30

Is avacopan better than prednisone for respiratory ANCA-associated vasculitis outcomes?

Presented By
Prof. Ulrich Specks, Mayo Clinic, MN, USA
Trial
Phase 3, ADVOCATE
Conference
ATS 2022

18 July, 2022 11:56

Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL

Expert
Dr Grzegorz Nowakowski, Mayo Clinic, Rochester, USA
Trial
Cohort study, RE-MIND2
Conference
ASH 2021

4 February, 2022 11:08

POLARIX: Novel regimen superior to R-CHOP in DLBCL

Presented By
Prof. Hervé Tilly, University of Rouen, France
Trial
Phase 3, POLARIX
Conference
ASH 2021

4 February, 2022 10:56

Ibrutinib continues to outperform chemoimmunotherapy in patients with treatment-naïve CLL

Expert
Dr Jennifer Woyach, Ohio State University, OH, USA
Trial
Phase 3, Alliance A041202
Conference
ASH 2021

3 February, 2022 23:22

Vaccine booster improves immune response in patients treated with rituximab

Presented By
Prof. Michael Bonelli, Medical University of Vienna, Austria
Conference
ACR 2021

14 January, 2022 11:07

Ultra-low dosing of rituximab in RA is a viable treatment option

Presented By
Mr Nathan den Broeder, Sint Maartenskliniek, the Netherlands
Trial
REDO
Conference
ACR 2021

14 January, 2022 10:58

Sequential rituximab after belimumab does not improve disease control in SLE

Presented By
Prof. Cynthia Aranow, Feinstein Institutes for Medical Research, NY, USA
Trial
Phase 3, BLISS-BELIEVE
Conference
ACR 2021

14 January, 2022 10:02

ASH 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
ASH 2021

4 January, 2022 08:00

Rituximab most effective initial MS therapy in Swedish real-world study

Presented By
Mr Peter Alping, Karolinska Institutet, Sweden
Trial
Phase 4, COMBAT-MS
Conference
ECTRIMS 2021

9 December, 2021 14:36

MS patients at risk of hampered immune response after vaccination

Presented By
Prof. Maria Pia Sormani, University of Genoa, Italy
Conference
ECTRIMS 2021

9 December, 2021 10:49

Anti-CD20 antibodies associated with worse COVID-19 outcomes

Presented By
Dr Steve Simpson-Yap, University of Melbourne, Australia
Conference
ECTRIMS 2021

9 December, 2021 10:41

Acquired TTP: new treatments and updated guidelines

Presented By
Dr María Mingot-Castellano, Hospital Universitario Virgen del Rocío, Spain
Trial
HERCULES; TITAN
Conference
EHA 2021

5 August, 2021 15:25

Fixed 12 cycles and MRD-guided venetoclax consolidation effective in CLL

Presented By
Dr Mark-David Levin, Albert Schweitzer Hospital, the Netherlands
Trial
Phase 2, HOVON 139/GiVe
Conference
EHA 2021

5 August, 2021 13:38

MATRix with ASCT: best long-term survival for primary CNS lymphoma

Presented By
Dr Gerald Illerhaus, Klinikum der Landeshauptstadt Stuttgart, Germany
Trial
Phase 2, IELSG32
Conference
EHA 2021

5 August, 2021 12:05

Naratuximab emtansine + rituximab safe and effective in diffuse large B-cell lymphoma

Presented By
Dr Moshe Yair Levy, Texas Oncology-Baylor Charles A. Sammons Cancer Center, USA
Conference
EHA 2021

5 August, 2021 11:55

JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA

Presented By
Dr Anja Strangfeld, German Rheumatism Research Centre Berlin, Germany
Conference
EULAR 2021

2 August, 2021 23:53

Rituximab or JAK inhibitors increase the risk of severe COVID-19

Presented By
Dr Jeffrey Sparks, Brigham and Women’s Hospital, MA, USA
Conference
EULAR 2021

2 August, 2021 23:36

Updates on COVID-19 vaccines in patients with rheumatic disease

Presented By
Dr Victoria Furer, Tel Aviv Sourasky Medical Center, Israel
Conference
EULAR 2021

2 August, 2021 22:44

JAK inhibitors and bDMARDs show comparable effectiveness

Presented By
Mr Andrei Barbulescu, Karolinska Institutet, Sweden
Conference
EULAR 2021

2 August, 2021 10:23

MS therapies influence COVID-19 severity

Conference
AAN 2021

16 June, 2021 11:42

Remission with rituximab in refractory generalised myasthenia gravis

Conference
AAN 2021

16 June, 2021 11:39

Do anti-CD20 DMTs cause worse COVID-19 outcomes in MS?

Presented By
Dr Steve Simpson-Yap, Melbourne School of Population and Global Health, Australia
Journal
Physician’s Weekly
Conference
MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting

15 April, 2021 16:27

Rheumatoid arthritis and interstitial lung disease: a deadly combination

Presented By
Prof. Joan Bathon, Columbia University, USA
Conference
ACR 2020

18 January, 2021 10:59

Poor disease control: a risk factor for severe COVID-19

Presented By
Prof. Rebecca Grainger, University of Otago, New Zealand
Trial
COVID-19 Global Rheumatology Alliance Registry
Conference
ACR 2020

18 January, 2021 10:57

Lupus nephritis: new therapies on the horizon in 2020

Presented By
Prof. Joan T. Merrill, Oklahoma Medical Research Foundation, USA
Conference
ACR 2020

18 January, 2021 10:54

Anti-CD20 DMTs associated with worse COVID-19 outcomes

Conference
MS Virtual 2020

25 November, 2020 17:09

Low-dose rituximab as effective as high-dose, but safer

Conference
MS Virtual 2020

25 November, 2020 16:57

Efficacy and safety of rituximab in refractory MG corroborated

Presented By
Dr A Dos Santos, University Hospital of Nantes, France
Conference
EAN 2020

10 September, 2020 14:24

Switching from natalizumab to moderate- versus high-efficacy DMT

Presented By
Dr Carrie M. Hersh, Cleveland Clinic Lerner College of Medicine, OH, USA
Conference
EAN 2020

10 September, 2020 12:17

Rituximab maintenance superior to azathioprine in ANCA-associated vasculitis

Presented By
Dr Rona Smith, University of Cambridge, UK
Trial
RITAZAREM
Conference
ACR 2019

4 February, 2020 23:18

Few serious infections in offspring with exposure to non-TNFi biologics or tofacitinib

Presented By
Dr Evelyne Vinet, McGill University, Montreal, Canada
Conference
ACR 2019

4 February, 2020 23:12

Tocilizumab outperforms rituximab in RA patients with low level of synovial B cell infiltration

Presented By
Prof. Costantino Pitzalis, Barts and The London School of Medicine and Dentistry, UK
Conference
ACR 2019

4 February, 2020 20:10

Rituximab beats mycophenolate mofetil in pemphigus vulgaris

Presented By
Prof. Pascal Joly, Rouen University Hospital, France
Trial
Phase 3, PEMPHIX, Ritux 3
Conference
EADV 2019

9 December, 2019 19:52

Risk of hypogammaglobulinemia and rituximab

Presented By
Dr Susanna Hallberg, Karolinska Institute, Sweden
Conference
ECTRIMS 2019

8 November, 2019 21:18

ASCEND study: Acalabrutinib improves progression-free survival in relapsed/refractory CLL

Presented By
Dr Paolo Ghia, Vita-Salute San Raffaele University, Italy
Trial
Phase 3, ASCEND
Conference
EHA 2019

9 August, 2019 15:28

Rituximab/lenalidomide regimen shows clinical benefit in non-hodgkin lymphoma trials

Trial
MAGNIFY, AUGMENT
Conference
ASCO 2019

15 July, 2019 14:17

Promising results rituximab in systemic sclerosis, and systemic lupus erythematosus classification criteria

Presented By
Prof. Allanore, University of Paris Descartes University, France
Conference
EULAR 2018

24 August, 2018 22:49

Combining new drugs with different mechanisms

Trial
EXPLORER
Conference
ECCO 2018

28 May, 2018 23:31
site created by:   

© 2021 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy